Updates are available Correction dated 2025-07-04

Article History

Received: 9 August 2024

Revised: 6 March 2025

Accepted: 27 March 2025

First Online: 16 April 2025

Change Date: 4 July 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00417-025-06889-4

Declarations

:

: This article does not contain any studies with human participants or animals performed by any of the authors.

: The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE) and did not receive payment related to the development of this manuscript. Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations.CMGC reports receiving funding from Bayer, Boehringer Ingelheim, Iveric Bio, Novartis, Roche, Topcon Healthcare, and ZEISS.YC reports receiving consulting fees from AbbVie, Astellas, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Novartis, and Roche.FGH reports receiving research grants and consulting fees from Acucela, Allergan, Apellis, Bayer, Bioeq/Formycon, Geuder, Heidelberg Engineering, Iveric Bio, Novartis, Pixium Vision, Roche/Genentech, and ZEISS; and consulting fees from Aerie Pharmaceuticals, Alexion, Alzheon, Annexon, Astellas, Boehringer Ingelheim, Graybug Vision, Janssen, Lin BioScience, Oxurion, and Stealth BioTherapeutics.AT reports receiving funding from Alcon Japan, AMO Japan, Bayer Yakuhin, Canon, Chugai Pharmaceutical, Findex, Otsuka Pharmaceutical, Rohto Nitten, Santen Pharmaceutical, Senju Pharmaceutical, Sumitomo Pharma, and Wakamoto Pharmaceutical; consultancy for Bayer Yakuhin, Chugai Pharmaceutical, Janssen, Kyowa Kirin, Nippon Boehringer Ingelheim, Novartis, Senju Pharmaceutical, and Sumitomo Pharma; and research funding from Alcon Japan, AMO Japan, Bayer Yakuhin, Canon, Chugai Pharmaceutical, Ellex, Johnson & Johnson, Kowa Pharmaceutical, MSD, NIDEK, Nikon Solutions, Novartis, Otsuka Pharmaceutical, Rohto Pharmaceutical, Santen Pharmaceutical, Senju Pharmaceutical, and Wakamoto Pharmaceutical.SS reports receiving consulting fees from 4DMT, AbbVie, Alexion, Allergan, Alnylam Pharmaceuticals, Amgen, Apellis Pharmaceuticals, Astellas, Bayer Healthcare Pharmaceuticals, Biogen, Boehringer Ingelheim, Catalyst Pharmaceuticals, Centervue/iCare, Genentech, Heidelberg Engineering, Hoffmann-La Roche, Iveric Bio, Janssen, Nanoscope, Notal Vision, Novartis, Optos, Oxurion/ThromboGenics, Oyster Point Pharma, Regeneron Pharmaceuticals, Samsung Bioepis, and Topcon Medical Systems; honoraria from Carl Zeiss Meditec, Heidelberg Engineering, NIDEK, Novartis, and Topcon Medical Systems; and research Instruments from Carl Zeiss Meditec, Centervue/iCare, Heidelberg Engineering, Optos, NIDEK, and Topcon.